Kilitch Drugs (India) Ltd Q2 FY26 – When a Pharma Company Decides to Go Full Throttle on Africa, Greenfield Projects, and Rights Issues
1. At a Glance
Let’s start with some spicy facts. Kilitch Drugs (India) Ltd — the 47-year-old pharma player — is currently trading at ₹342 per share with a market cap of ₹598 crore. Over the last 3 months, the stock has basically done yoga — moved a little, stretched a bit, and returned to where it started, down 3.6%. The company recently reported a quarterly PAT of ₹8.04 crore on sales of ₹48.92 crore. With a P/E of 21.7x, an ROCE of 15.7%, and an ROE of 12.6%, this mid-tier pharma is trying hard to look fancy in a party full of billion-dollar giants like Sun Pharma and Cipla.
Debt stands at ₹83.6 crore, a manageable level given their ongoing ₹100 crore greenfield project at Khopoli, Maharashtra. They’ve even raised ₹49.93 crore via a rights issue at ₹357/share in November 2025 — because why borrow from banks when you can borrow from your shareholders?
Exports account for about 59% of total revenue, with Africa being the main love story. And in a Bollywood-style twist, their Ethiopian subsidiary bagged a USD 9.13 million tender from the Ethiopian government for pharmaceutical supply. Not bad for a company that started in 1978 with just tablets and tonics.
2. Introduction
Pharma in India is like cricket — everyone wants to play, but only a few hit centuries. Kilitch Drugs is that middle-order batsman who occasionally surprises with a six over cover. Incorporated in 1978, the company has transformed from a local formulations maker into a global exporter of injectables, tablets, and effervescent medicines, with operations spread across India, Africa, and Latin America.
The stock has been on a decent run, delivering a 30% CAGR over the last five years, and that too without paying a single rupee in dividends. (Investors might call it stingy; management calls it “strategic reinvestment.”)
Over the past decade, Kilitch has grown its sales from ₹108 crore in FY12 to ₹209 crore in FY25, a 26% 10-year CAGR. Profit has grown even faster at a 42% CAGR — which is how you make pharma look like fintech.
But let’s not sugarcoat it — the company’s high debtor days (156) and promoter holding dip (down 5.46% to 63.8%) are giving auditors heartburn. Still, Kilitch seems determined to carve its niche through exports, niche formulations, and that Ethiopian connection that’s paying serious dividends (well, metaphorically).
3. Business Model – WTF Do They Even Do?
Kilitch Drugs makes and markets a range of pharmaceutical formulations in solid, liquid, and parenteral forms. Fancy words, but basically, they sell tablets, capsules, syrups, injectables, and even effervescent powders that make you feel like your medicine is having a soda party.
They operate in five main verticals:
Parenterals & Nasal products (ampoules, vials, injectables) — think of everything your nurse injects with that fake smile.
Oral & Nutritional Products — antibiotics, anti-diabetics, and multivitamins like ROIPAR and 9-VIT.
Effervescent Tablets — bubbly medicines that fizz faster than your soda.
Medical Devices — includes the C-SEAL, a CE-certified topical skin adhesive.
Cosmetic & Herbal Products — because why sell antibiotics when you can sell hair lotion and libido supplements too?
Their manufacturing setup includes:
A WHO & FDA-approved plant in Mumbai.
A Cephalosporin facility in Ethiopia, operated via subsidiary Kilitch Estro Biotech PLC (KEB).
And coming soon: a ₹100 crore greenfield plant at Khopoli, which is expected to go live in 2025.
It’s a mix of pharma seriousness with entrepreneurial hustle — kind of like Ranveer Singh in a lab coat.
4. Financials Overview
Let’s get to the real spice — the Q2 FY26 numbers (Sept 2025).
Metric (₹ Cr)
Latest Qtr (Sep 25)
YoY (Sep 24)
Prev Qtr (Jun 25)
YoY %
QoQ %
Revenue
48.92
47.47
43.14
3.05%
13.4%
EBITDA
5.04
6.10
3.26
-17.4%
54.6%
PAT
8.04
8.61
2.27
-6.6%
254.4%
EPS (₹)
4.69
4.93
1.73
-4.9%
171.0%
Annualised EPS = 4.69 × 4 = ₹18.76, so P/E (CMP ₹342) ≈ 18.2x, slightly below the 21.7x trailing P/E.
Commentary: Revenue growth is mild, but the profit rebound QoQ is dramatic — Kilitch pulled off a pharma comeback like a patient recovering from a cold with 10 antibiotics. Margins were soft YoY, thanks to higher raw material costs and likely African logistics chaos, but PAT margin at 16.4% still shows solid control.
5. Valuation Discussion – Fair Value Range Only
Let’s get nerdy (without making you cry).
Method 1: P/E Valuation Industry average P/E: 31.5x Kilitch current P/E: 21.7x Annualised EPS = ₹18.76 Fair Value Range = ₹18.76 × (18x – 26x) = ₹338 – ₹488
Method 2: EV/EBITDA EV = ₹649 Cr, EBITDA (FY25 TTM) = ₹44.4 Cr EV/EBITDA = 14.6x (already decent for mid-cap pharma) Peer average EV/EBITDA ≈ 16–20x Fair Value Range (on EBITDA basis): ₹400 – ₹520
Disclaimer: This fair value range is for educational purposes only and is not investment advice.
6. What’s Cooking – News, Triggers, Drama
November 2025 was eventful. Kilitch completed a rights issue worth ₹49.93 crore at ₹357 per share, issuing 13.98 lakh shares. The proceeds will fund the Pen project (part of Khopoli expansion) and bolster working capital.
The company also reported H1 FY26 PAT of ₹10.3 crore, meaning it’s on track to surpass FY25 if the second half doesn’t go full telenovela.
And the Ethiopian love story continues — subsidiary Kilitch Estro Biotech PLC (KEB) bagged a USD 9.13 million (₹75 crore) contract from Ethiopia’s Pharmaceutical Supply Service. Imagine being paid by an entire country — it’s like getting a cheque signed by Africa itself.
Add to that the auditor switch in August 2024, where Suryaprakash Maurya & Co. exited and C Sharat & Associates joined the drama. Classic “old
